Dorfman pooling enhances SARS-CoV-2 large-scale community testing efficiency.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
12
2022
accepted:
16
03
2023
medline:
19
4
2023
entrez:
18
4
2023
pubmed:
19
4
2023
Statut:
epublish
Résumé
PCR-based analysis is the gold standard for detection of SARS-CoV-2 and was used broadly throughout the pandemic. However, heightened demand for testing put strain on diagnostic resources and the adequate amount of PCR-based testing required exceeded existing testing capacity. Pooled testing strategies presented an effective method to increase testing capacity by decreasing the number of tests and resources required for laboratory PCR analysis of SARS-CoV-2. We sought to conduct an analysis of SARS-CoV-2 pooling schemes to determine the sensitivity of various sized Dorfman pooling strategies and evaluate the utility of using such pooling strategies in diagnostic laboratory settings. Overall, a trend of decreasing sensitivity with larger pool sizes was observed, with modest sensitivity losses in the largest pools tested, and high sensitivity in all other pools. Efficiency data was then calculated to determine the optimal Dorfman pool sizes based on test positivity rate. This was correlated with current presumptive test positivity to maximize the number of tests saved, thereby increasing testing capacity and resource efficiency in the community setting. Dorfman pooling methods were evaluated and found to offer a high-throughput solution to SARS-CoV-2 clinical testing that improve resource efficiency in low-resource environments.
Identifiants
pubmed: 37071604
doi: 10.1371/journal.pgph.0001793
pii: PGPH-D-22-01934
pmc: PMC10112776
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0001793Informations de copyright
Copyright: © 2023 Burtniak et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Biosaf Biosecur. 2021 Jun;3(1):1-3
pubmed: 33521591
Stat Med. 2021 Aug 30;40(19):4185-4199
pubmed: 34046930
BMJ Glob Health. 2022 Feb;7(2):
pubmed: 35165095
Front Public Health. 2021 Aug 18;9:583377
pubmed: 34490172
J Med Virol. 2021 Mar;93(3):1568-1572
pubmed: 32936471
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
IEEE Open J Signal Process. 2021 Apr 27;2:248-264
pubmed: 34812422
Transfusion. 2002 Aug;42(8):975-9
pubmed: 12385406
Clin Biochem Rev. 2020 Dec;41(3):79-92
pubmed: 33343043
Trends Mol Med. 2020 May;26(5):483-495
pubmed: 32359479
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666
pubmed: 32442256
Diagn Microbiol Infect Dis. 2020 Nov;98(3):115125
pubmed: 32768876
Diagn Microbiol Infect Dis. 2021 Oct;101(2):115432
pubmed: 34175613
EMBO Mol Med. 2020 Jun 8;12(6):e12634
pubmed: 32375201
Int J Infect Dis. 2021 Feb;103:19-22
pubmed: 33220439
Epidemics. 2020 Dec;33:100413
pubmed: 33187884